Novartis: 1996 – 2013 Dr Daniel Vasella was the first CEO of the newly merged company. Vasella was hired by Sandoz back in 1988 and remained there until 1992 when he was promoted to CEO of its ...
Novartis has already declared that a one-time treatment of the drug will cost $475,000 - within the range predicted by analysts, but much lower than the $1 million forecasts made initially.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback